This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Random-start controlled ovarian stimulation and double ovarian stimulation have been proposed for efficient oocyte retrieval within the limited time before cancer therapy. We aimed to clarify the efficacy of these new protocols within the Japanese population.
| INTRODUC TI ON
Thus, in addition to embryo freezing, oocyte freezing has become a common method of FP. However, oocyte and embryo cryopreservation need ovarian stimulation, which results in increased serum estradiol levels that may accelerate breast cancer growth. In order to avoid estradiol elevation, the protocol of ovarian stimulation with aromatase inhibitor (AI) was proposed, 5 as the protocol is unlikely to increase recurrence risk in breast cancer. 6 Normally, ovarian stimulation begins in the early follicular phase.
Because there is often the need to start cancer treatment at the earliest convenience, random-start ovarian stimulation, in which ovarian stimulation begins in the luteal phase, has been proposed in order to avoid waiting until the next menstruation. [7] [8] [9] To harvest more oocytes efficiently within the limited time available before starting cancer treatment, double ovarian stimulation (DuoStim) within the same menstrual cycle was proposed. 10, 11 DuoStim provides a greater opportunity for retrieving oocytes within a short period. Oocytes from follicular phase ovarian stimulation (FPS) and luteal phase ovarian stimulation (LPS) have similar developmental potential, and subsequent frozen embryo transfer provides optimal pregnancy outcomes. 11, 12 As there are no published reports concerning random-start ovarian stimulation and DuoStim among the Japanese population, here we examined the efficacy of these protocols in Japan.
| MATERIAL S AND ME THODS

| Study patients
We performed a multicenter retrospective observational study among patients who underwent FP from February 2012 to August 2017. The breast cancer patients were referred by the oncologist for consults on FP. Follow-up information concerning cancer recurrence was collected from the medical records of oncologists or from patient interviews. (Figure 1 ).
| Breast cancer subtypes
The luteal phase was defined as detection of the corpus luteum by ultrasound sonography or elevated serum progesterone (>2 ng/mL).
We performed sequential second ovarian stimulation after the first ovum pick up without waiting until the next menstruation in the DuoStim protocol ( Figure 1 ).
| Oocytes and embryo cryopreservation
Oocyte 
| Statistical analysis
Paired and unpaired t tests and Fisher's exact test were performed to compare differences between two groups. Statistically significant difference was defined as P < 0.05.
| RE SULTS
Fifty cycles of ovum pick up among 34 patients were analyzed Characteristics of FPS and LPS are shown in Table 1 . The two groups were comparable in mean age at OPU, AMH level, and baseline FSH. Although the number of retrieved oocytes and rate of mature oocytes were not different between the two groups, number of days stimulated and total FSH/HMG dose were higher in the luteal F I G U R E 2 Flowchart of fertility preservation for breast cancer patients. Oocyte and embryo freezing together were performed in three cycles F I G U R E 3 Characteristics of breast cancer. A, Stages of breast cancer. B, Intrinsic subtypes of breast cancer phase group (9.0 ± 1.9 days vs 11.3 ± 2.6 days, 1290.5 ± 586.2 IU vs 1957.1 ± 1030.2 IU, respectively). Fertilization rates using IVF and ICSI were not significantly different between the two groups.
The numbers of frozen oocytes and embryos in FPS and LPS are shown in Table 2 . There was no significant difference between the two groups.
We divided the cases into two groups in terms of letrozole dose in a subgroup analysis (Table 3) . Although there was no significant difference, there was a trend in that serum peak E2 level was lower in the 5 mg group. The number of retrieved oocytes was not different between the two groups. Although total FSH/HMG dose was higher in the 5 mg group, it could be related that there were more LPS cycles in the 5 mg group.
We divided the cases into two groups depending on whether menstruation occurred between first ovum pick up and the start of The number of second-retrieved oocytes was not decreased compared to the number of first-retrieved oocytes in either the Conventional stimulation or DuoStim (Table 4) .
There were no cases of cancer recurrence among the 28 patients for whom we had follow-up data. Mean follow-up period after ovum pick up was 459 days. Although four embryos among two patients were transferred, there were no clinical pregnancies.
| D ISCUSS I ON
In the present study, we found that nearly same number of oocytes/ embryos were cryopreserved between FPS and LPS using the letrozole protocol. Furthermore, the number of second oocytes retrieved in DuoStim was not decreased compared to the first oocyte retrieval. Although the observational time was relatively short, cancer recurrence was not observed during the study period.
TA B L E 1 Characteristics of FPS and LPS
FPS (n = 29) LPS (n = 21) P
The number of retrieved oocytes in the LPS was similar to that of the FPS. This result was consistent with the findings reported in previousstudies. 15, 16 A previous study showed that there was no elevated rate of abnormality at birth after LPS compared to FPS. 17 Another study showed that euploid blastocyst rate calculated either per biopsied blastocyst or injected MII oocyte was not significantly different between FPS and LPS groups. 10 A previous study showed that 35-to 37-year-old women needed to cryopreserve about 20 mature oocytes to have an 80% chance of obtaining at least one successful pregnancy. 18 In the present study, the mean numbers of frozen oocytes were 7.4 and 5.1 per ovum pick up in FPS and LPS, respectively. Therefore, about three cycles of ovum pick up were needed to have an 80% chance of at least one successful pregnancy.
Random-start and DuoStim were efficient strategies for obtaining more oocytes within the limited time available.
Although an association between the use of letrozole for infertility treatment and congenital anomalies was reported in a relatively small number of pregnancies, 19 such an association was rejected in recent studies. [20] [21] [22] In general, letrozole 2.5 or 5 mg per day was used for ovarian stimulation. 5, 7 Although the difference in serum peak E2 level did not reach statistical significance, there was a trend in that serum peak E2 level was lower in the 5 mg compared to 2.5 mg group.
Serum peak E2 level in the 5 mg per day-letrozole group was controlled to about 400 pg/mL, which is comparable to the natural ovulatory cycle. 23 The number of retrieved oocytes was similar in spite of the lower serum E2 level and higher average age of patients in the 5 mg group. These results were probably due to the fact that we could administer enough FSH/HMG without causing elevation of serum E2.
Therefore, administration of 5 mg/d letrozole was effective, particularly in the estrogen receptor-positive breast cancer patients.
Several breast cancer risk factors have been identified, and estrogen exposure is one example. 24, 25 Although our study involved a relatively short observational period, we note that there were no recurrent breast cancer patients among patients given FP with letrozole. This result suggested that ovarian stimulation with letrozole does not have a great influence on the recurrence rate for breast cancer during at least short periods; this is consistent with the results of a previous study that followed patients for a longer time period. 6 In this study, we used letrozole during ovarian stimulation regardless of the existence of estrogen receptor. 
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